CureVac (CVAC) PT Lowered to $47 at Credit Suisse, Following Clinical Trial Update
Tweet
Share
E-mail
Get Alerts CVAC Hot Sheet
Price: $4.66 --0%
Rating Summary:
1 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
1 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Credit Suisse analyst Martin Auster lowered the price target on CureVac (NASDAQ: CVAC) to $47.00 (from $52.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Navios Maritime Partners (NMM) PT Raised to $100 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
